[Implications of the immunologic response to the graft in the design of immunosuppressive treatment for liver transplantation].
de la Mata
M
M
Unidad de Trasplante Hepático, Hospital Universitario Reina Sofía, Avda. Menéndez Pidal, s/n, 14004 Córdoba, España.
Barrera
P
P
Montero
J L
JL
Fraga
E
E
Briceño
J
J
Pozo
J C
JC
Solórzano
G
G
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000601:surgery; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D019090:Case Management; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D015658:HIV Infections / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation; D012306:Risk; D013601:T-Lymphocytes
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents